Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02040103
Other study ID # RC12-045
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 16, 2014
Est. completion date November 13, 2018

Study information

Verified date December 2018
Source King Abdullah International Medical Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients admitted to the intensive care unit are at high risk of developing clots in the veins of the lower extremities. The objective of this study is to examine whether the use of a device that provides intermittent compression to the legs in addition to the use of low-dose blood thinners, provides an additional protection when compared to the use of blood thinners alone. Patients who are admitted to the intensive care unit are receiving low-dose blood thinners to prevent clots are candidates for this study. Patients who are enrolled will continue to receive blood thinners but some will additionally receive the leg compression. The additional use of leg compression may provide protection from clots. The main side effect is possible skin abrasions but this is usually mild. The study is sponsored by King Abdullah International Medical Research Center(KAIMRC) and King Abdulaziz City for Science and Technology(KACST) and will be conducted in several hospitals in Saudi Arabia, Canada, Australia, Brazil and possibly other countries. The study started July 2014 and is to continue for 4 years.


Description:

There is no randomized controlled trial examining effect of the adjunct use of IPC with pharmacologic prophylaxis compared to pharmacologic prophylaxis (UFH, LMWH) alone in critically ill patients for VTE prevention.


Recruitment information / eligibility

Status Completed
Enrollment 2000
Est. completion date November 13, 2018
Est. primary completion date November 13, 2018
Accepts healthy volunteers No
Gender All
Age group 14 Years and older
Eligibility INCLUSION CRITERIA

A. Medical-Surgical ICU patients >14 years old at participating ICU. ICUs that use other age cut-off for adult patients will adhere to their local standard (16 or 18 years) B. Weight > 45kg C. Expected ICU LOS> 72hrs D. Eligible for pharmacologic thromboprophylaxis with UFH and LMWH.

EXCLUSION CRITERIA

A. Patient treated with IPC for > 24 hours in this current ICU admission. B. Patient in the ICU> 48 hours. C. Patient treated with pharmacologic VTE prophylaxis with medications other than UFH or LMWH.

D. Inability or contraindication to applying IPC to both legs i.Burns in the lower extremities, lacerations, active skin infection, & ischemic limb in the legs at the site of IPC placement ii. Acute ischemia in the lower extremities iii. Amputated foot or leg on one or two sides iv. Compartment Syndrome v. Severe peripheral arterial disease vi. Vein ligation, gangrene, recent vein grafts, and draining incisions vii. Evidence of bone fracture in lower extremities E. Therapeutic dose of anticoagulation with UFH or LMWH F. Pregnancy G. Limitation of life support, life expectancy < 7 days or palliative care H. Allergy to the sleeves material I. Patients with Inferior Vena Cava (IVC) Filter

Study Design


Intervention

Device:
pneumatic compression
All IPC devices intended for DVT prophylaxis are acceptable in the study. Sequential devices (cuffs have several chambers) are preferred, but non-sequential (cuffs have single chambers) are acceptable.

Locations

Country Name City State
Saudi Arabia Intensive Care Unit, King Abdulaziz Medical City, National Guard Health Affairs Riyadh

Sponsors (16)

Lead Sponsor Collaborator
King Abdullah International Medical Research Center Assir Central Hospital, Gosford Hospital, Australia, King Abdulaziz Hospital, Al Ahsa, King Abdulaziz Medical City, Jeddah, King Fahad Hospital of the University, Al Khobar, King Fahad Medical City, King Faisal Specialist Hospital & Research Center, Jeddah, King Faisal Specialist Hospital & Research Center, Riyadh, King George's Medical University, India, Medanta, The Medicity, India, Mount Sinai Hospital, Canada, Prince Sultan Military Medical City, Royal North Shore Hospital, St Vincent's Hospital - Sydney, Australia, St. Michael's Hospital, Toronto

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type Measure Description Time frame Safety issue
Other ICU Length of stay and duration of mechanical ventilation ICU Length of stay: Number of calendar days between admission and discharge from ICU.
Duration of mechanical ventilation: Number of calendar days between start and end of mechanical ventilation.
Number of days in ICU with an average expected duration of 10 days and number of days of mechanical ventillation with an expected average duration of 8 days.
Primary Proximal deep vein thrombosis(DVT) diagnosed by compression ultrasound The primary outcome is incident proximal leg DVT, defined as detected 3 or more days post-randomization and up to ICU discharge or day 28 post randomization 28 days from randomization
Secondary Pulmonary Embolism Pulmonary Embolism: will be followed up to ICU discharge or day 28 post randomization.
ICU Mortality. Death in ICU during the same ICU admission. Hospital Mortality. Death in the hospital (in ICU or on ward) during the same hospital admission. (Hospital mortality will be censored at 1 year from the date of enrollment).
28-day Mortality: Death before or at day 28 of enrollment. 90-day Mortality: Death before or at day 90 of enrollment.
from the time of randomization to 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT02889562 - Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Phase 2/Phase 3
Completed NCT01333618 - Introducer Curving Technique for Tilt of Transfemoral Günther Tulip Inferior Vena Cava Filter N/A
Completed NCT00812370 - The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids Phase 1
Completed NCT02552420 - The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism Phase 2/Phase 3
Completed NCT00178789 - Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis Phase 1/Phase 2
Completed NCT03251963 - Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients Phase 2
Completed NCT03286985 - The Prevalence and Incidence of DVT in General ICU
Completed NCT04414332 - Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry
Completed NCT02211326 - Genotype-guided Warfarin Individualized Treatment N/A
Completed NCT03296280 - Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
Recruiting NCT03937583 - Screening for Cancer in Patients With Unprovoked VTE Phase 4
Completed NCT00628576 - Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities Phase 3
Completed NCT04979026 - Clinical Investigation of a Novel Approach for the Prevention of Deep Venous Thrombosis After Total Knee Replacement N/A
Active, not recruiting NCT02318472 - Early Mobilization After Achilles Tendon Rupture N/A
Completed NCT01221805 - STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism Phase 4
Recruiting NCT03740633 - Functional Training for the Prevention of Deep Venous Thrombosis Phase 3
Completed NCT03707665 - Deep Venous Thrombosis Screening in the ICU by Nurses
Recruiting NCT05171049 - A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Phase 3
Completed NCT01542723 - Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy N/A